Intestinal fibrosis is a serious complication in inflammatory bowel disease (IBD). Despite the remarkable success of recent anti-inflammatory therapies for IBD, incidence of intestinal fibrosis and need for bowel resection have not significantly changed. To clarify the contribution of haematopoietic-derived cells in intestinal fibrosis, we prepared bone marrow (BM) chimeric mice (chimeras), which were reconstituted with BM cells derived from enhanced green fluorescent protein (EGFP)-transgenic mice or CC chemokine receptor 2 (CCR2)-deficient mice. After 2 months of transplantation, BM chimeras were treated with azoxymethane/dextran sodium sulphate. During chronic inflammation, CCR2+BM-derived monocyte and fibrocyte infiltration into the colon and CC chemokine ligand 2 production increased, leading to colon fibrosis in EGFP BM chimeras. In CCR2-deficient BM chimeras, monocyte and fibrocyte numbers in the colonic lamina propria significantly decreased, and colon fibrosis was attenuated. In colon tissue, mRNA expression of tissue inhibitor of metalloproteinase (TIMP)-1 but not of collagen I, transforming growth factor-β1 or matrix metalloproteinases was significantly different between the two chimeras. CCR2+monocytes and fibrocytes showed highTimp1mRNA expression. Our results suggest that infiltrating CCR2+monocytes and their progenies, fibrocytes, promote colon fibrosis by inhibiting collagen degradation through TIMP-1 production.
1 August 2020 in Clinical Gastroenterology and Hepatology
A 65-year-old man was referred to our hospital with obstructive jaundice. Laboratory tests showed elevated levels of alkaline phosphatase (1932 U/L; normal range 35 – 104 U/L), γ-glutamyltransferase (1030 U/L; normal value < 39 U/L), and bilirubin (3.6 mg/dL; normal value < 1.2 mg/dL). The tumor antigen CA 19-9 was also elevated (226.4 U/L; normal value < 37 U/L). Abdominal computed tomography showed a well-demarcated mass in the head of the pancreas ([Fig. 1]). This was 4 cm in diameter with a heterogeneous enhancing pattern. Endoscopic retrograde cholangiopancreatography showed a smooth stricture of the distal common bile duct ([Fig. 2]), and a plastic biliary stent (8.5 Fr, 7 cm) was inserted into the bile duct. Although endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was carried out ([Fig. 3]), definitive diagnoses could not be made because the samples from EUS-FNA contained only normal-looking pancreatic tissue. Pancreaticoduodenectomy was performed. Microscopically, the specimen showed a well-demarcated solid mass ([Fig. 4]), and the tumor was composed of non-neoplastic acinar and ductal cells embedded in a hypocellular fibrous stroma ([Fig. 5]). Immunohistochemically, the spindle-shaped stromal cells were positive for CD34 and negative for c-kit. The ductal components were positive for S-100. The histological diagnosis was pancreatic hamartoma. There was no evidence of recurrence up to 3 years after surgery. Pancreatic hamartoma is a non-neoplastic, mass-forming lesion of the pancreas and is extremely rare. The pathogenesis of these tumors remains unknown. The major histopathological features of pancreatic hamartoma are mature acini and small to medium-sized ducts showing a distorted architecture with various amounts of fibrous stroma. Immunohistochemically, the ductal components are positive for S-100 and the spindle-shaped stromal cells express CD34 and/or c-kit [1] [2]. Weight loss and abdominal pain are the most common symptoms characterizing pancreatic hamartoma. To the best of our knowledge, our report describes the first case of pancreatic hamartoma manifesting initially as obstructive jaundice. Endoscopy_UCTN_Code_CCL_1AF_2AZ_3AB
29 February 2016 in Case Reports in Gastroenterology
The clinical characteristic of gastrointestinal anisakiasis is severe abdominal pain after eating raw fish. Intestinal anisakiasis is more uncommon than gastric anisakiasis. Most patients with intestinal anisakiasis need hospitalization because anisakiasis can cause intestinal obstruction, ileus, peritonitis or intestinal perforation. We report a case of intestinal anisakiasis. A 43-year-old woman presented with symptoms of intermittent abdominal pain 2 days after eating raw fish. Her brother had eaten the same food and had been suffering from gastric anisakiasis. Abdominal ultrasonography in this patient showed localized jejunal wall thickening with dilated lumen of proximal jejunum and ascites. According to the clinical course and examinations, she was diagnosed with intestinal anisakiasis. Administration of prednisolone 5 mg/day and olopatadine hydrochloride 10 mg/day improved her symptoms quickly without hospitalization. Prednisolone was administered for 10 days, and olopatadine hydrochloride was administered for a total of 6 weeks according to ultrasonographic findings. Six months after the treatment, the abdominal ultrasonography demonstrated normal findings. This case demonstrates that ultrasonography was quite useful for the diagnosis and surveillance of intestinal anisakiasis. Furthermore, treatment with corticosteroid and an antiallergic agent could be an option for patients with intestinal anisakiasis.
We aimed to confirm the effect of combined treatment with celecoxib and rebamipide would be more effective than celecoxib alone for prevention of upper gastrointestinal (GI) events. Patients with rheumatoid arthritis, osteoarthritis, and low back pain were enrolled in this study. Patients were randomized to two groups: a monotherapy group (100 mg celecoxib twice daily) and a combination therapy group (add on100 mg of rebamipide three times a day). The GI mucosal injury was evaluated by endoscopic examination before treatment and at 3 months. The primary endpoint was to evaluate the preventive effect of the combination therapy group for GI events, endoscopic upper GI ulcers and intolerable GI symptoms, compared with the monotherapy group. Seventy-five patients were enrolled. Sixty-five patients were analyzed (16 males, 49 females; mean age: 67 ± 13 years). The prevalence of upper GI events, five of endoscopic GI ulcers and one of intolerable GI symptoms, were 6/34 (17.6 %) in the monotherapy group and 0/31 in the combination therapy group, p = 0.0252. The combination therapy group was more effective than the monotherapy group for prevention of upper GI events in this study. Rebamipide might be a candidate for an option to prevent COX-2 selective inhibitor-induced upper GI events.